Shenzhen Hemogen
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. (NCT06655662) | Shenzhen Hemogen | 2024-06-12 |
| the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia (NCT05851105) | Shenzhen Hemogen | 2022-10-08 |
| the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia (NCT05864170) | Shenzhen Hemogen | 2022-05-27 |
| Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients (NCT05745532) | Shenzhen Hemogen | 2020-12-01 |
Track Shenzhen Hemogen automatically
Every clearance here is in the API, with alerts when new ones post.